FDA fast-tracks empagliflozin for improving patient outcomes following a heart attack

Michael Walter | | Cardiovascular Business | Acute Coronary Syndromes

Boehringer Ingelheim and Eli Lilly and Company announced Tuesday, Sept. 15, that the FDA has granted a a Fast Track designation for the development of empagliflozin to improve patient outcomes following an acute myocardial infarction (ACI). The designation covers both patients with and without diabetes.

Empagliflozin, sold under the name Jardiance, is used to lower blood sugar in patients with type 2 diabetes. It is also prescribed to help reduce the risk of cardiovascular death in patients with type 2 diabetes and known cardiovascular disease.

“Ischemic heart disease (IHD) is the leading cause of death and disability in the U.S.,” Mohamed Eid, MD, MPH, MHA, vice president of clinical development and medical affairs for Boehringer Ingelheim’s cardio-metabolism and respiratory medicine division, said in a statement. “Myocardial infarction, or heart attack, is the deadliest acute manifestation of IHD, and treatment options are urgently needed to help improve outcomes.”

“The FDA Fast Track designation for Jardiance is an important milestone towards addressing an unmet need for people who have had a heart attack,” Jeff Emmick, MD., PhD, vice president of product development for Lilly, said in the same statement. “We remain committed to finding breakthrough outcomes for people with and without type 2 diabetes, including the prevention and treatment of heart failure.”

The EMPACT-MI trial is currently underway, with Boehringer Ingelheim and Lilly investigating the effect of empagliflozin on ACI patients.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed
New report raises questions about data that helped heart drug gain FDA approval
American College of Cardiology now supports early use of medication to treat obesity
Cannabis is bad for the heart—should the risk be taken more seriously?
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B
Meditation linked to ‘real, lasting benefits’ for high-risk heart patients

Around the web

Health Exec
Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations. 

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.